X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (11) 11
cancer (7) 7
melanoma (6) 6
metastasis (6) 6
aged (5) 5
care and treatment (5) 5
chemotherapy (5) 5
clinical trials (5) 5
dermatology (5) 5
female (5) 5
male (5) 5
middle aged (5) 5
oncology (5) 5
skin (5) 5
treatment outcome (5) 5
adult (4) 4
antineoplastic agents - therapeutic use (4) 4
hematology, oncology and palliative medicine (4) 4
medical colleges (4) 4
medicine, general & internal (4) 4
melanoma - drug therapy (4) 4
mutation (4) 4
open-label (4) 4
survival (4) 4
tumors (4) 4
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer therapies (3) 3
disease-free survival (3) 3
double-blind method (3) 3
medicine & public health (3) 3
melanoma - genetics (3) 3
metastases (3) 3
mutations (3) 3
protein kinase inhibitors - therapeutic use (3) 3
skin neoplasms - pathology (3) 3
skin neoplasms - therapy (3) 3
vemurafenib (3) 3
abridged index medicus (2) 2
alanine (2) 2
alanine transaminase (2) 2
allergology (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents, alkylating - therapeutic use (2) 2
benzimidazoles - administration & dosage (2) 2
cancer-immunotherapy (2) 2
combined modality therapy (2) 2
dacarbazine - administration & dosage (2) 2
dacarbazine - therapeutic use (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
drug eruptions - diagnosis (2) 2
follow-up studies (2) 2
immunology (2) 2
immunotherapy (2) 2
improved survival (2) 2
kaplan-meier estimate (2) 2
medical research (2) 2
melanoma - mortality (2) 2
melanoma - secondary (2) 2
melanoma - therapy (2) 2
neoplasm staging (2) 2
pharmaforum (2) 2
proctology (2) 2
proto-oncogene proteins b-raf - antagonists & inhibitors (2) 2
pyridines - therapeutic use (2) 2
radiotherapy (2) 2
resistance (2) 2
review (2) 2
review article (2) 2
skin cancer (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - etiology (2) 2
skin neoplasms - mortality (2) 2
solid tumors (2) 2
survival rate (2) 2
ultraviolet rays - adverse effects (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
acne conglobata (1) 1
acral erythema (1) 1
activating transcription factor 3 - metabolism (1) 1
acute coronary syndromes (1) 1
age (1) 1
age distribution (1) 1
agent (1) 1
alanine transaminase - blood (1) 1
algorithms (1) 1
american joint committee (1) 1
amicrobial pustulosis (1) 1
aminolevulinate photodynamic therapy (1) 1
analgesics (1) 1
anilides - therapeutic use (1) 1
animals (1) 1
antibodies (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - therapeutic use (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer
Journal Article
The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10151, pp. 971 - 984
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of the disease differ widely across the globe depending on access to early... 
LYMPH-NODE DISSECTION | HIGH-RISK MELANOMA | MEDICINE, GENERAL & INTERNAL | TERT PROMOTER MUTATIONS | DABRAFENIB PLUS TRAMETINIB | STAGE-III MELANOMA | PRIMARY CUTANEOUS MELANOMA | OPEN-LABEL | INVESTIGATOR-CHOICE CHEMOTHERAPY | INDIVIDUAL PATIENT DATA | AMERICAN JOINT COMMITTEE | Melanoma - epidemiology | Melanoma - etiology | Age Distribution | Neoplasm Metastasis - therapy | Skin Neoplasms - therapy | Humans | Risk Factors | Antineoplastic Agents - therapeutic use | Skin Neoplasms - epidemiology | Ultraviolet Rays - adverse effects | Incidence | Randomized Controlled Trials as Topic | Sunlight - adverse effects | Mass Screening | Protein Kinase Inhibitors - therapeutic use | Skin Neoplasms - mortality | Skin Neoplasms - etiology | Melanoma - therapy | Neoplasm Staging | Melanoma - mortality | Medical colleges | Mortality | Melanoma | Antibodies | Metastasis | Epidemiology | Viral antibodies | Analysis | Skin | Mitogens | Protein kinases | Germany | Medical informatics | Medical innovations | Clinical trials | Raf protein | Family medical history | Kinases | Cancer therapies | Metastases | Skin cancer | Proteins | Signal transduction | Age | Containment | Medical research | Threonine | MAP kinase | Protein kinase inhibitors | Survival | Chemotherapy | Sunburn & sun tanning | Inhibitors | Cell death | Mutation | Health risk assessment | Prolongation | Cancer | Tumors
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 03/2017, Volume 15, Issue 3, pp. 350 - 352
Journal Article
Journal of Dermatological Science, ISSN 0923-1811, 11/2018, Volume 92, Issue 2, pp. 172 - 180
Due to their immunosuppressive therapy, organtransplant recipients (OTRs) exhibit a high incidence for the development of cutaneous squamous cell carcinoma... 
Sirolimus | Cutanous squamous cell carcinoma | ATF3 | TARGET | RAPAMYCIN INHIBITORS | RISK | RENAL-TRANSPLANT RECIPIENTS | DERMATOLOGY | NONMELANOMA SKIN-CANCER | IMMUNOSUPPRESSION | SQUAMOUS-CELL CARCINOMA | CALCINEURIN | SWITCH | KIDNEY | Skin - cytology | Keratinocytes - radiation effects | Carcinogenesis - chemically induced | Carcinoma, Squamous Cell - pathology | Humans | Carcinogenesis - radiation effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Skin Neoplasms - prevention & control | Cell Culture Techniques | Oncogenes | Skin - pathology | Skin Neoplasms - pathology | Sirolimus - therapeutic use | Down-Regulation | Carcinoma, Squamous Cell - prevention & control | Activating Transcription Factor 3 - metabolism | Sirolimus - pharmacology | Ultraviolet Rays - adverse effects | Calcineurin Inhibitors - adverse effects | Carcinoma, Squamous Cell - etiology | Keratinocytes - pathology | Keratinocytes - drug effects | Keratinocytes - metabolism | Skin - radiation effects | Cyclosporine - adverse effects | Organ Transplantation - adverse effects | Cell Line, Tumor | Immunosuppressive Agents - adverse effects | Skin Neoplasms - etiology | Skin - drug effects | Medical research | Squamous cell carcinoma | Immunotherapy | Skin care products | Radiation | Medicine, Experimental | Genetic aspects | Skin | Immunosuppressive agents
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2013, Volume 11, Issue 11, pp. 1041 - 1046
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 09/2010, Volume 8, Issue 9, pp. 652 - 661
Summary The hand‐foot‐syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy‐associated acral erythema) is characterized by painful predominantly... 
erythrodysesthesia | medical tumor therapy | hand‐foot‐syndrome | palmoplantar | PEGYLATED LIPOSOMAL DOXORUBICIN | ACRAL ERYTHEMA | ERYTHRODYSAESTHESIA SYNDROME | CUTANEOUS TOXICITY | KINASE INHIBITORS SORAFENIB | hand-foot-syndrome | DERMATOLOGY | PALMAR-PLANTAR ERYTHRODYSESTHESIA | SKIN REACTION | PHASE-II TRIAL | METASTATIC BREAST-CANCER | PYRIDOXINE THERAPY | Niacinamide - analogs & derivatives | Foot Dermatoses - classification | Keratoderma, Palmoplantar - diagnosis | Foot Dermatoses - diagnosis | Foot Dermatoses - therapy | Hand Dermatoses - classification | Humans | Drug Eruptions - therapy | Hand Dermatoses - chemically induced | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Dermatologic Agents - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - toxicity | Dose-Response Relationship, Drug | Drug Eruptions - diagnosis | Keratoderma, Palmoplantar - classification | Keratoderma, Palmoplantar - chemically induced | Pyridines - therapeutic use | Drug Administration Schedule | Hand Dermatoses - therapy | Drug Eruptions - classification | Antineoplastic Combined Chemotherapy Protocols - toxicity | Neoplasms - drug therapy | Pyridines - toxicity | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Foot Dermatoses - chemically induced | Keratoderma, Palmoplantar - therapy | Protein Kinase Inhibitors - toxicity | Hand Dermatoses - diagnosis | Benzenesulfonates - toxicity | Chemotherapy | Cancer | Tumors
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 04/2011, Volume 34, Issue 2, pp. 10 - 12
Journal Article
Journal Article